CN1739799A - Compound recipe for treating osteoarthrosis - Google Patents
Compound recipe for treating osteoarthrosis Download PDFInfo
- Publication number
- CN1739799A CN1739799A CN 200510029437 CN200510029437A CN1739799A CN 1739799 A CN1739799 A CN 1739799A CN 200510029437 CN200510029437 CN 200510029437 CN 200510029437 A CN200510029437 A CN 200510029437A CN 1739799 A CN1739799 A CN 1739799A
- Authority
- CN
- China
- Prior art keywords
- osteoarthritis
- prescription
- compound prescription
- sulfate
- chitosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to one kind of composition and its use. The compound recipe for treating osteoarthrosis has glucosamine sulfate as main component. Specifically, the compound recipe contains glucosamine sulfate 30-90 wt%, frankincense extract 0.01-40 wt%, pineapple proteinase 0.01-45 wt%, and tangeritin 0.01-20 wt%. The frankincense extract is obtained through the process including crushing frankincense, thrice heated alcohol solution reflux, merging the extracted liquid, purification, concentrating and stoving at lower temperature. The compound recipe can prevent and treating various kinds of arthritis and improve the symptoms of arthritis as well as preventing and treating osteoporosis.
Description
Technical field
A kind of compound prescription that is used for osteoarthritis of the present invention relates to a kind of compositions and purposes.
Background technology
Osseous arthritis (osteoarthritis, hypertrophy, traumatic arthritis etc.) is the common disease that influences middle-aged and elderly people health, has 40% knee joint clinical symptoms of different degrees just to occur approximately as the women more than 40 years old.Osteoarthritis is a kind of pathological state that shows in the human synovial organ collpase process, and osteoarticular cartilage matrix and synovial membrane surface are damaged and run off, and promptly cause various symptoms.Degenerative osteoarthritis and various joint injury comprise the traumatic bone arthritis that arthrotrauma, operation cause, and are clinical common still unsolved again problems.In recent years, articular cartilage protection theory, especially osamine class medicine is used as Chondroprotective agents; make the research field of osteoarthritis obtain developing; to the generation of prevention osseous arthritis or alleviate lesion degree, relief of symptoms and improve function of joint has become an active subject day by day.
Glucamine is that human body itself can own synthetic a kind of amino sugar.It is precursor or an essential element of making proteoglycan and mucosa, and proteoglycan then is the main component that osteoarthrosis is asked cartilage.Slit at structure cartilage, periosteum liquid, muscle band, skin, fingernail, eyes, bone, in the mucosa of cardiac valve and digestive system, glucamine is served as very key player.Studies show that in the conjunctive tissue of body iliacus joint, the glucosamine component content is quite high, it has the generation that promotes collagen protein, increases the combination of water, helps to repair functions such as damage cartilage.Therefore, glucosamine is considered to make injured cartilage to recover normal, and periosteum liquid is denseer, toughness more, thus to the generation of prevention osseous arthritis or alleviate lesion degree, relief of symptoms and improve function of joint plays good effect.According to the literature: the seventies in last century, European medical circle just is used for the treatment of arthritis with glucamine, develops into some countries in Asia afterwards, the direct called after of glucosamine sulphate " ammonia joint, Portugal rope " that Canada produces.It is reported that existing now more than 70 national registration glucosamine sulphate is used for the treatment of arthritis, and extensive use in millions of patients.China is at this class medicine " glucosamine " of Italian import (Viartril ' s), and at " national essential drugs " (Western medicine) of listing 1998 in.
Manyly both at home and abroad the research report aspect the osteoarthritis treatment is shown that glucamine is the most effective specific drug up to now, can significantly alleviate inflammation and pain that osteoarthritis causes at glucosamine hydrochloride, glucosamine sulphate.Full of leaves and Hou Chunlin with glucamine to rabbit knee joint wound after in cartilage injury's the protective effect research; experimental group is put into 2% chitosamine sulfate solution 1ml in articular cavity; matched group is used the tubulose plaster fixation, respectively at putting to death in 3,6 weeks of postoperative.The result shows that the degeneration of experimental group knee joint X-ray film lightens, and range of motion is greater than matched group (P＜0.01), histology's light microscopic and transmission electron microscope observing, and the experimental group cartilage is smooth, and cartilage thickness is normal, and morphocytology is normal substantially.The prompting chitosamine sulfate has the protection articular cartilage, delays the effect of regression.Wu Haishan, Hou Chunlin makees kneed osteoarthritis model on animal body, postoperative every 3 days in intraarticular injection 2% chitosamine sulfate solution 1ml, respectively at 4,8,12 weeks of operation back with sacrifice of animal, carry out light microscopic and transmission electron microscope observing, the result shows that chitosan can prevent traumatic articular degeneration.The Li Nan of Nanjing University, the Li Ji of China Medicine University don't, be used for the treatment of arthrosis with glucamine hydrochlorate and chitosamine sulfate respectively, can significantly alleviate inflammation and pain that osteoarthritis causes.Discover that in the body iliacus conjunctive tissue, the glucosamine component content is the highest, it has the generation that promotes collagen protein, increases the combination of water, helps to repair the cartilage function of damage.Abroad once the someone did following clinical experiment, 30 examples are suffered from the osteoarthritis patient be divided into two groups, treat with conventional medicament for one group, treat with chitosamine sulfate for one group, the result obviously alleviates with several all backs of chitosamine sulfate treatment symptom, and curative effect obviously is better than matched group.In addition 20 routine gonarthritis patients are divided into chitosamine sulfate treatment group and psychology comfort treatment group, in 8 weeks of the course of treatment, the group of chitosamine sulfate treatment as a result pain relief, arthroncus and weakness symptom obviously are better than comforting the treatment group.
Summary of the invention
The object of the present invention is to provide a kind of compound prescription that is used for osteoarthritis.
Prescription provided by the invention be a kind of be the composite formula of Main Ingredients and Appearance with the chitosamine sulfate, each component content is:
Chitosamine sulfate 30%-90%
Olibanum extract 0.01%-40%
Bromelain 0.01%-45%
Tangeritin 0.01%-20%
Wherein, the extraction process of described Olibanum extract is: with the Olibanum of cleaning, 40 ℃ of oven drying at low temperatures are pulverized then, with low solubility alcoholic solution reflux 2-3 hour, extracts three times, merge extractive liquid,, carry out purification process after, concentrated, oven drying at low temperature gets final product.
Described low solubility alcoholic solution is 40-60%;
Described purification process is meant by modes such as flocculation reaction, pH sedimentation and resin absorptioies carries out purification process.
The present invention can be made into multiple dosage forms such as capsule, packed powdered agent.The adult takes 500-1000mg, every day 1-2 time at every turn.
Principle of the present invention is: this prescription is to be main component with the glucamine, and it is preventing and treating osteoarthritis, alleviates ailing aspect, various joints and should have good effect; Simultaneously, in order further to strengthen the effectiveness of preventing and treating the arthritis aspect of this prescription, also increased other three kinds of compositions with fine auxiliary effect in prescription, they are respectively Olibanum extract, bromelain, citrus flavone.Olibanum comes from the Olibanum plant, is used for the arthrosis treatment by Indian therapist for a long time, is the good material that alleviates arthralgia, and scientific research confirms, treats osteoarthritis and rheumatic arthritis with Olibanum, can protect the joint epiphysial cartilage to wreck; Bromelain is a kind of good natural antiinflammatory, and certain effect that alleviates various arthritic symptoms is arranged; Biological flavone is a kind of antioxidant, can prevent and treat or alleviate the damage of radical pair articular cartilage, delays arthritic severity of symptoms.Therefore, reasonably combined, the synergism of these several effective ingredient can be prevented and treated multiple arthritis such as osteoarthritis fully and effectively, improves arthritic various symptom.
Superiority of the present invention is: discover that this prescription be except preventing and treating various arthritis and improving the symptom due to the arthritis, can also prevent and treat and improve the various symptoms due to the osteoporosis.
The specific embodiment
Embodiment
Compound prescription of the present invention can have multiple combination, and following only is wherein several examples.
Prescription 1:
Every 500mg compound prescription contains following concrete composition:
Chitosamine sulfate 400mg
Olibanum extract 20mg
Bromelain 70mg
Citrus pyrite 10mg
Wherein, the extraction process of described Olibanum extract is: with the Olibanum of cleaning, 40 ℃ of oven drying at low temperatures, pulverize then, with the low solubility alcoholic solution reflux of 40-60% 2-3 hour, extract merge extractive liquid, three times, after carrying out flocculation reaction, pH sedimentation and resin absorption purification process, concentrated, oven drying at low temperature gets final product.
Prescription 2:
Every 500mg compound prescription contains following concrete composition:
Chitosamine sulfate 200mg
Olibanum extract 130mg
Bromelain 150mg
Citrus pyrite 20mg
Prescription 3:
Every 500mg compound prescription contains following concrete composition:
Chitosamine sulfate 450mg
Olibanum extract 18mg
Bromelain 25mg
Citrus pyrite 7mg
Application examples
Compound prescription is to the observation of the various remission situations due to the arthritis
Choose 120 examples and suffer from the outpatient of gonarthritis and be divided into 2 groups at random and test, the battery of tests group is taken compound prescription 445mg, 2 times/day; Another group is taken placebo (vitamin C) 200mg, 2 times/day for matched group; Take 8 time-of-weeks altogether, observe the curative effect.Discover that the various symptoms of test group patient's arthritis all are clearly better than matched group, have significant difference, see Table 1 compound prescription the alleviation situation of arthritic symptom is observed.Do not see drug-induced untoward reaction.
Table 1 compound prescription is observed the alleviation situation of arthritic symptom
| Medicine | Joint stiffness | Arthralgia | The friction sense | Arthroncus |
| Compound prescription vitamin C P value | 86.6％ (52/60) 30.1％ (19/60) P＜0.05 | 93.3％ (56/60) 20.2％ (13/60) P＜0.05 | 80.0％ (48/60) 18.3％ (11/60) P＜0.05 | 70.1％ (43/60) 30.0％ (21/60) P＜0.05 |
Claims (4)
1, a kind of compound prescription that is used for osteoarthritis is the composite formula of Main Ingredients and Appearance with the chitosamine sulfate, and each component content is:
Chitosamine sulfate 30%-90%
Olibanum extract 0.01%-40%
Bromelain 0.01%-45%
Tangeritin 0.01%-20%
Wherein, the extraction process of described Olibanum extract is: clean Olibanum is pulverized,, is extracted three times with low solubility alcoholic solution reflux 2-3 hour, merge extractive liquid,, carry out purification process after, concentrated, oven drying at low temperature gets final product.
2. a kind of compound prescription that is used for osteoarthritis according to claim 1 is characterized in that: described low solubility alcoholic solution is 40-60%.
3. a kind of compound prescription that is used for osteoarthritis according to claim 1 is characterized in that: described purification process is meant by a kind of mode in flocculation reaction, pH sedimentation and the resin absorption or more than one mode.
4. a kind of compound prescription that is used for osteoarthritis according to claim 1 is characterized in that: make a kind of dosage form in capsule, the powdered agent with described prescription.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510029437 CN1739799A (en) | 2005-09-06 | 2005-09-06 | Compound recipe for treating osteoarthrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510029437 CN1739799A (en) | 2005-09-06 | 2005-09-06 | Compound recipe for treating osteoarthrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1739799A true CN1739799A (en) | 2006-03-01 |
Family
ID=36092421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510029437 Pending CN1739799A (en) | 2005-09-06 | 2005-09-06 | Compound recipe for treating osteoarthrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1739799A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181369B (en) * | 2007-11-29 | 2010-09-29 | 北京中科雍和医药技术有限公司 | Compound prescription for curing osteoarthropathy as well as preparation technique thereof |
| CN101721340B (en) * | 2009-10-23 | 2012-02-15 | 无限极（中国）有限公司 | Cosmetic composition for delaying skin aging |
| CN102641458A (en) * | 2012-04-17 | 2012-08-22 | 肖贵成 | Preparation method for medicated implanted catgut sutures for treating neck, shoulder, waist and leg pain and spinal diseases |
| CN108741099A (en) * | 2018-06-11 | 2018-11-06 | 广州尚天诚品生物科技有限公司 | One kind contributing to comfortable alimentation composition in joint and its preparation method and application |
-
2005
- 2005-09-06 CN CN 200510029437 patent/CN1739799A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181369B (en) * | 2007-11-29 | 2010-09-29 | 北京中科雍和医药技术有限公司 | Compound prescription for curing osteoarthropathy as well as preparation technique thereof |
| CN101721340B (en) * | 2009-10-23 | 2012-02-15 | 无限极（中国）有限公司 | Cosmetic composition for delaying skin aging |
| CN102641458A (en) * | 2012-04-17 | 2012-08-22 | 肖贵成 | Preparation method for medicated implanted catgut sutures for treating neck, shoulder, waist and leg pain and spinal diseases |
| CN108741099A (en) * | 2018-06-11 | 2018-11-06 | 广州尚天诚品生物科技有限公司 | One kind contributing to comfortable alimentation composition in joint and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1907410A (en) | Chinese traditional medicine preparation for treating bone fracture and traumatic injury | |
| CN101732521A (en) | Medicinal composition for treating fracture and preparation method thereof | |
| CN1739799A (en) | Compound recipe for treating osteoarthrosis | |
| CN100339102C (en) | Medicinal plaster for treating sinew and bone tissue injury pain, bone fracture, dislocation | |
| CN1927256A (en) | Upper, middle and lower part soup, and method for making same | |
| CN107823634A (en) | Treatment medicine for treating osteoporosis based on marine polysaccharide | |
| CN1823929A (en) | Medicine for treating dandruff | |
| WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
| EP2149378B1 (en) | Topical formulations for the symptomatic treatment of musculoskeletal disorders | |
| CN1189197C (en) | Traditional Chinese medicine having effects of reducing inflammation, stopping blooding, stopping pain, promoting blood circulation and promoting tissue regeneration | |
| CN100411661C (en) | Amber bolus | |
| KR20190044823A (en) | Composition for treating muscular skeletal disease | |
| CN108939058A (en) | A kind of Chinese materia medica preparation and preparation method of promoting blood circulation and stopping pain | |
| CN1290540C (en) | Oral admnistration Chinese medicine for treating bone fracture and matched topically applied Chinese medicine | |
| JP2007326839A (en) | Health food products with an aim to improve diabetes, periodontal diseases and arthritis | |
| WO2021042276A1 (en) | Combination drug for treating osteoarthritis | |
| Tiwari et al. | Comparative evaluation of the potential anti-spasmodic activity of Piper longum, Piper nigrum, Terminalia bellerica, Terminalia chebula, and Zingiber officinale in experimental animals | |
| CN1132587C (en) | Preparation method of medicine for curing surgical diseases of traditional Chinese medicine | |
| WO2021042274A1 (en) | Traditional chinese and western medicine composition for treating osteoarthritis | |
| CN1301544A (en) | Medicinal composition for curing arthritis and osteoarthropathy and its preparing method | |
| CN1237426A (en) | Chinese patent medicine for external application for curing diseases of scald, burn and dermal ulcer | |
| CN1085093C (en) | Traditional Chinese medicine oral liquor for treating male infertility | |
| CN1443547A (en) | Ointment for curing acne and its preparation method | |
| CN1248697C (en) | Medicinal composition for treating chronic enteritis and its preparing process | |
| CN106539910B (en) | Traditional Chinese medicine composition containing radix aconiti and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20060301 |